Dibyakanti Mishra is a Scientist and industry professional with deep expertise in neurodegenerative disorders. Her PhD research from Indian Institute of Technology Delhi (IIT Delhi) focused on elucidating the role of optineurin gene mutations in Amyotrophic Lateral Sclerosis (ALS) through cellular studies and whole-exome sequencing of Indian ALS patient DNA, advancing understanding of disease mechanisms and potential therapeutic pathways. Post PhD, she served as a Scientist and Project Investigator at Sun Pharma Advanced Research Company Ltd., where she led and optimized key studies in the neurodegenerative disease domain using advanced biological research methodologies. Currently, She leads techno-commercial initiatives at Topia Lifesciences Ltd. and Topia Medtech Ltd., spearheading the launch of a cutting-edge neurodiagnostic software platform designed for early and precise identification of neurological disorders. Their work bridges scientific research, innovation, and real-world clinical application, with a strong focus on collaborative R&D and translational impact.